Table 4.

Multinomial Regression Analyses to Investigate Genetic Associations with Multimorbidity State Persistence

	Model 1 (n = 1,463)				Model 2 (n = 1,463)
	MM at 1 TP (n = 84)		MM at 2–5 TPs (n = 205)		MM at 1 TP (n = 84)		MM at 2–5 TPs (n = 205)
	RRR (95% CI)	P Value	RRR (95% CI)	P Value	RRR (95% CI)	P Value	RRR (95% CI)	P Value
Wheeze state in early life	3.00 (1.33–6.76)	0.008	1.00 (0.51–1.95)	1.000	3.00 (1.33–6.77)	0.008	1.00 (0.51–1.95)	1.000
Eczema state in early life	39.65 (20.58–76.39)	<0.001	19.72 (12.64–30.77)	<0.001	39.60 (20.54–76.37)	<0.001	19.73 (12.64–30.79)	<0.001
Filaggrin loss-of-function mutation	0.88 (0.37–2.10)	0.771	1.75 (1.05–2.92)	0.032	0.40 (0.07–2.23)	0.298	1.53 (0.57–4.15)	0.399
rs7216389	1.03 (0.71–1.49)	0.881	1.49 (1.15–1.94)	0.003	0.95 (0.64–1.42)	0.814	1.48 (1.11–1.96)	0.007
Filaggrin*rs7216389	—	—	—	—	2.01 (0.60–6.80)	0.260	1.13 (0.54–2.39)	0.743
Male	0.96 (0.57–1.63)	0.892	1.06 (0.73–1.53)	0.753	0.96 (0.57–1.62)	0.882	1.06 (0.73–1.53)	0.753

Definition of abbreviations: CI = confidence interval; MM = multimorbidity; RRR = relative risk ratio; TP = time point.

For rs7216389, an additive (dosage) model was used, where the number of risk alleles was treated as a continuous variable in the regression analysis, where 0 = CC (homozygous for the C allele), 1 = CT (heterozygous [one C and one T allele]), and 2 = TT (homozygous [two T alleles]). Outcome is 0: no MM; 1: MM at 1 TP; 2: MM at 2–5 TPs. No MM is the omitted category. Boldface represents coefficients that are significant at P ⩽ 0.05.